Jazz enrolls first patient in JZP-110’s phase 2 trial for excessive sleepiness in PD patients
The clinical study will be conducted across approximately 15 centers in the United States. Jazz Pharmaceuticals research and development global head and development and chief medical officer Karen
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.